Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Net Income towards Common Stockholders (2016 - 2025)

Rocket Pharmaceuticals' Net Income towards Common Stockholders history spans 10 years, with the latest figure at -$42.5 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 29.49% year-over-year to -$42.5 million; the TTM value through Dec 2025 reached -$223.1 million, up 13.77%, while the annual FY2025 figure was -$223.1 million, 13.77% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$42.5 million at Rocket Pharmaceuticals, up from -$50.3 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$34.5 million in Q2 2021 and bottomed at -$69.6 million in Q2 2024.
  • The 5-year median for Net Income towards Common Stockholders is -$59.0 million (2023), against an average of -$55.9 million.
  • The largest annual shift saw Net Income towards Common Stockholders plummeted 72.35% in 2021 before it rose 29.49% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$44.2 million in 2021, then plummeted by 50.8% to -$66.7 million in 2022, then rose by 10.59% to -$59.7 million in 2023, then dropped by 1.12% to -$60.3 million in 2024, then grew by 29.49% to -$42.5 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Net Income towards Common Stockholders are -$42.5 million (Q4 2025), -$50.3 million (Q3 2025), and -$68.9 million (Q2 2025).